PCR inhibition in stool samples in relation to age of infants

Sami Oikarinen1, Sisko Tauriainen, Hanna Viskari

  • 1JDRF Center for the Prevention of Type 1 Diabetes in Finland, Finland. Sami.Oikarinen@uta.fi

Insights

PCR inhibitors are common in children's stool samples, potentially causing false negatives. Adding bovine serum albumin (BSA) effectively neutralizes these inhibitors, ensuring accurate PCR testing.

Area of Science:

  • Molecular Biology
  • Clinical Diagnostics
  • Pediatric Gastroenterology

Background:

  • Polymerase Chain Reaction (PCR) is increasingly used in diagnostic virology.
  • PCR inhibitors in clinical samples can lead to inaccurate false-negative results.

Purpose of the Study:

  • To investigate the prevalence of PCR inhibitors in stool samples from children aged 3 to 24 months.
  • To explore the relationship between age, diet, and inhibitor presence.
  • To assess methods for overcoming PCR inhibition.

Main Methods:

  • Stool samples were collected from children aged 3-24 months.
  • Extracted RNA was spiked with Semliki Forest Virus RNA and amplified via PCR.
  • Inhibition was quantified by comparing amplification rates to controls.
  • Dietary influence was assessed by comparing samples from exclusively breastfed vs. non-exclusively breastfed infants.
  • The efficacy of bovine serum albumin (BSA) in mitigating inhibition was tested.

Main Results:

  • 12% of samples showed complete and 19% partial PCR inhibition.
  • Inhibition was not detected in infants under 6 months but present in 17% of older infants (6-24 months).
  • Breastfeeding was more prevalent in younger infants.
  • Addition of BSA completely eliminated inhibitory effects, yielding positive results for all samples.

Conclusions:

  • PCR inhibitors are frequently found in children's stool samples.
  • Dietary components may contribute to PCR inhibition.
  • BSA is a simple and effective agent for neutralizing stool-derived PCR inhibitors, improving diagnostic accuracy.
Abstract

Related Concept Videos

Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from the skin...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...